openPR Logo
Press release

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Insight and Therapeutic Assessment Reviewed, H2 2017

08-18-2017 07:26 AM CET | Health & Medicine

Press release from: Healthcare Industry Market Report - MRH

MRH

MRH

Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2017” to its report offerings. The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297802

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Review, H2 2017, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Acute Pain, Allergic Asthma, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), Chronic Pain, Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener Polyangiitis), Huntington Disease, Inflammatory Pain, Kidney Disease, Lung Cancer, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Neuropathic Pain, Periodontitis and Rheumatoid Arthritis.

Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read Full Report with TOC: http://www.marketresearchhub.com/report/c5a-anaphylatoxin-chemotactic-receptor-1-cd88-or-c5ar1-pipeline-review-h2-2017-report.html

Table of Contents:
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Overview 6
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 18

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297802

About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:
90 State Street,
Albany, NY 12207,
United States
Toll Free: 1-800-998-4852 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: www.marketresearchhub.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Insight and Therapeutic Assessment Reviewed, H2 2017 here

News-ID: 673383 • Views: 161

More Releases from Healthcare Industry Market Report - MRH

Global Pressure Relief Mattress Market Analysis, Competitor Analysis, Choice Mod …
The global pressure relief mattress market is growing steadily at a CAGR of 4.63%, owing to rise in demand from individual end-users and healthcare providers, who are looking for better patient care services. Long-term bed-ridden patients in hospitals or in-home care and older adults are more prone to develop pressure ulcers due to lack of mobility. Growing demand for pressure relief mattress from such patients are driving the market growth. Request
Global Hearing Protection Devices Market Segmentation and Analysis by Market Res …
Hearing protection devices are used to protect the human ear from hearing loss due to occupational and other harmful noise. These products reduce noise exposure levels and the risk of hearing loss. These devices have been in existence since the early 1900s, but in the US, the use of these devices in offices and workshops was not controlled by law until 1971. Request A Free Sample Report- http://www.marketresearchhub.com/enquiry.php?type=S&repid=1320831 The Market Research
Global Healthcare Fabrics Sales Market Report : Share, Growth, Size, Trends and …
Market Research Hub (MRH) has recently added a new report to its vast online database. This research study is titled as “Global Healthcare Fabrics Sales Market Report” 2017 which presents an in-depth study about the production, consumption, market volume, revenue (million USD) and market share across different geographical regions. In this report, the global Healthcare Fabrics market is valued at USD XX million in 2016 and is expected to
Vacation Animal Health Market Analysis, Outlook and Forecast Report Until 2021
Market Research Hub (MRH) has included the latest Forecast report titled “Vacation Animal Health Market Industry Analysis & Outlook (2017-2021)”, to its vast database. The report provides a comprehensive analysis of the global animal health market and its major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in-depth. Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1318871 Animals, like humans, also suffer from diseases and hence require

All 5 Releases


More Releases for C5a

Atypical Hemolytic Uremic Syndrome (aHUS) Therapeutics - Pipeline Analysis 2018, …
Atypical hemolytic uremic syndrome (aHUS), also known as non-diarrhea - associated hemolytic uremic syndrome, is a rare disease characterized by hemolytic anemia, thrombocytopenia, acute kidney failure and uremia. Download the sample report at: https://www.pharmaproff.com/request-sample/1036 The signs and symptoms of aHUS include formation of tiny blood clots in various small blood vessels of the body. These clots reduce or prevent proper blood flow to various organs of the body, especially the kidneys.
Global C5a Anaphylatoxin Chemotactic Receptor 1 Market 2019 By AFFiRiS AG, Chemo …
The trending C5a Anaphylatoxin Chemotactic Receptor 1 report represents a comprehensive study of the global C5a Anaphylatoxin Chemotactic Receptor 1 market. It includes the growth rate of the global C5a Anaphylatoxin Chemotactic Receptor 1 market for the estimated period. The global report summarizes by providing the estimated development of the C5a Anaphylatoxin Chemotactic Receptor 1 market in the upcoming period. It also highlights the key factors for the development of
Global C5a Anaphylatoxin Chemotactic Receptor 1 Market Trends, Overview and Indu …
A fresh report has been added to the wide database of Market Research Hub (MRH) titled “Global C5a Anaphylatoxin Chemotactic Receptor 1 Market Research Report (2018-2025)” which provides an outlook of current market value as well as the expected forecast of Rate on Investment (ROI) with growing CAGR of XX% by the end of 2025. The report also studies the C5a Anaphylatoxin Chemotactic Receptor 1 market worldwide, especially in North
C5a Anaphylatoxin Chemotactic Key Players – AFFiRiS AG, ChemoCentryx Inc, Domp …
C5a Anaphylatoxin Chemotactic Overview C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H1 2018, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development,
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Pipeline Review, H2 …
ReportsWorldwide has announced the addition of a new report title C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 (CD88
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Pipeline Review, H2 …
ReportsWorldwide has announced the addition of a new report title C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) – Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 (CD88